![Parand Darou Pharma](https://www.pharmacompass.com/image/flap/parand-darou-desktop-headergif-12950.gif)
![Parand Darou Pharma](https://www.pharmacompass.com/image/flap/parand-darou-mobgif-20656.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/harmony-biosciences-acquires-epygenix-therapeutics-inc-adding-late-stage-epilepsy-franchise-to-growing-pipeline-of-innovative-cns-assets-302131000.html
https://www.pharmiweb.com/press-release/2022-07-21/epygenix-therapeutics-to-participate-in-rw-bairds-biotech-discovery-series
https://www.contractpharma.com/contents/view_breaking-news/2022-03-15/epygenix-therapeutics-names-darren-cline-as-president-and-ceo/?widget=listSection
https://www.prnewswire.com/news-releases/epygenix-therapeutics-announces-fda-acceptance-of-ind-to-initiate-a-clinical-trial-of-epx-100-to-treat-lennox-gastaut-syndrome-301364855.html
https://www.prnewswire.com/news-releases/epygenix-therapeutics-announces-first-patient-successfully-dosed-in-phase-2-study-for-the-treatment-of-dravet-syndrome-with-epx-100-301171444.html
https://www.prnewswire.com/news-releases/epygenix-therapeutics-announces-first-patient-successfully-dosed-in-phase-2-study-for-the-treatment-of-dravet-syndrome-with-epx-100-301171444.html
https://www.prnewswire.com/news-releases/epygenix-therapeutics-announces-first-patient-enrolled-in-phase-2-study-for-the-treatment-of-dravet-syndrome-with-epx-100-301144613.html
https://www.prnewswire.com/news-releases/epygenix-therapeutics-initiates-phase-2-study-for-dravet-syndrome-with-epx-100-301133241.html